Next Article in Journal
Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream
Next Article in Special Issue
Role and Modulation of NK Cells in Multiple Myeloma
Previous Article in Journal
On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology
Previous Article in Special Issue
Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma
Review

Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates

Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081HV Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 6 February 2021 / Revised: 23 February 2021 / Accepted: 24 February 2021 / Published: 1 March 2021
In the 2010s, immunotherapy revolutionized the treatment landscape of multiple myeloma. CD38-targeting antibodies were initially applied as monotherapy in end-stage patients, but are now also approved by EMA/FDA in combination with standards-of-care in newly diagnosed disease or in patients with early relapse. The approved SLAMF7-targeting antibody can also be successfully combined with lenalidomide or pomalidomide in relapsed/refractory myeloma. Although this has resulted in improved clinical outcomes, there remains a high unmet need in patients who become refractory to immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies. Several new antibody formats, such as antibody–drug conjugates (e.g., belantamab mafodotin, which was approved in 2020 and targets BCMA) and T cell redirecting bispecific antibodies (e.g., teclistamab, talquetamab, cevostamab, AMG-420, and CC-93269) are active in these triple-class refractory patients. Based on their promising efficacy, it is expected that these new antibody formats will also be combined with other agents in earlier disease settings. View Full-Text
Keywords: multiple myeloma; immunotherapy; antibodies; monoclonal; bispecific; immunoconjugates; antibody-drug conjugates multiple myeloma; immunotherapy; antibodies; monoclonal; bispecific; immunoconjugates; antibody-drug conjugates
Show Figures

Figure 1

MDPI and ACS Style

Verkleij, C.P.M.; Bruins, W.S.C.; Zweegman, S.; van de Donk, N.W.C.J. Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. Hemato 2021, 2, 116-130. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010007

AMA Style

Verkleij CPM, Bruins WSC, Zweegman S, van de Donk NWCJ. Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. Hemato. 2021; 2(1):116-130. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010007

Chicago/Turabian Style

Verkleij, Christie P.M., Wassilis S.C. Bruins, Sonja Zweegman, and Niels W.C.J. van de Donk 2021. "Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates" Hemato 2, no. 1: 116-130. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2010007

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop